Pediatric Crohn Disease Activity Index PCDAI Calculator
Disease activity assessment
Score the child's symptoms over the past week, examination, growth, and laboratory findings. Select one response for each item.
Complete the ESR and albumin fields to calculate the score. Confirm all clinician-assessed items before interpretation.
PCDAI is a disease-activity instrument for children with Crohn disease. It does not independently establish diagnosis, endoscopic healing, or a treatment decision.
About PCDAI
The Pediatric Crohn Disease Activity Index combines patient-reported symptoms, physical examination and growth, and laboratory findings to characterize disease activity in children and adolescents with Crohn disease.
The original PCDAI uses 0, 5, or 10 points for most clinical/examination items and 0, 2.5, or 5 points for hematocrit and ESR. Albumin contributes 0, 5, or 10 points. Higher scores indicate greater activity.
Commonly used interpretation thresholds
| PCDAI score | Interpretation |
|---|---|
| <10 | Inactive disease / remission |
| 10–27.5 | Mild disease activity |
| 30–37.5 | Moderate disease activity |
| 40–100 | Severe disease activity |
These commonly used cutoffs are based on a later clinimetric appraisal; the original paper and other studies have also used simpler thresholds. Scores in the gaps shown are not expected from the conventional item increments.
Scoring notes
- Use the one-week recall period for history items.
- Height scoring differs between diagnosis and follow-up.
- Hematocrit thresholds depend on age and sex; the calculator asks the clinician to select the applicable category.
- A decrease greater than 12.5 points has been used as a clinically meaningful response in validation studies; interpret change with the clinical context.
References
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.